CEO Neil Kumar discussed the company’s late-stage pipeline, commercial execution priorities, and the evolving transthyretin amyloid cardiomyopathy (ATTR-CM) market in a conversation with Barclays ...

Small-cap stocks advanced in Q4, despite increased volatility that appeared primarily driven by government shutdown and concerns about capital spending for AI. Read more here.

BridgeBio Pharma (NASDAQ:BBIO) highlighted accelerating U.S. uptake for its transthyretin (TTR) stabilizer Attruby and laid ...

Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...

PGIM Jennison Health Sciences Fund outperformed its index in Q4 2025, led by Eli Lilly and Arcutis. Read the full analysis for more details.

Showcase your company news with guaranteed exposure both in print and online The San Francisco Business Times and the Silicon Valley Business Journal are proud to present… Celebrate owners/developers, ...